Advertisements
Feeds:
Posts
Comments

Search Results for 'CRISPR/Cas9'


Will the Supreme Court accept a UC Berkeley Appeal of the Sep. 10th, US Court of Appeals for the Federal Circuit decision to uphold the patent filed by the Broad Institute on CRISPR/Cas9 gene editing? Reporter: Aviva Lev-Ari, PhD, RN   On 2018, Sep. 10th, the US Court of Appeals for the Federal Circuit agreed to uphold the patent filed […]

Read Full Post »


On June 12, 2018 – Berkeley was granted a patent on using CRISPR/Cas9 to edit single-stranded RNA. On June 19, 2018 – Berkeley was granted a second patent, covering the use of CRISPR-Cas9 gene editing with formats that will be particularly useful in developing human therapeutics and improvements in food security. Reporter and Curator: Aviva Lev-Ari, PhD, RN […]

Read Full Post »


Reporter and Curator: Dr. Sudipta Saha, Ph.D.   The CRISPR-Cas9 system has proven to be a powerful tool for genome editing allowing for the precise modification of specific DNA sequences within a cell. Many efforts are currently underway to use the CRISPR-Cas9 system for the therapeutic correction of human genetic diseases. CRISPR/Cas9 has revolutionized our […]

Read Full Post »


Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing Reporter: Aviva Lev-Ari, PhD, RN [Boldface added] Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and […]

Read Full Post »


FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com Reporter: Aviva Lev-Ari, PhD, RN   FEBS Journal Special Issue on CRISPR FEBS Journal Special Issue on CRISPR/Cas9 The FEBS Journal The discovery of CRISPR in archaea and bacteria The FEBS Journal Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens The FEBS Journal […]

Read Full Post »


LIVE – The CRISPR/Cas9 Revolution and Gene Editing: 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM Reporter: Aviva Lev-Ari, PhD, RN Each year the recipient(s) of the Warren Alpert Foundation Prize are recognized at a scientific symposium hosted by Harvard Medical School. OCTOBER 6, 2016 – 1:30PM TO 5:30PM 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM The CRISPR/Cas9 […]

Read Full Post »


LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston http://www.discoveryontarget.com/ http://www.discoveryontarget.com/crispr-therapies/ Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a Media Partner of CHI for CHI’s 14th Annual Discovery on Targettaking place September 19 – 22, 2016 in Boston. In Attendance, streaming LIVE using Social Media […]

Read Full Post »


LIVE 9/19 1:40 – 3:20 EMERGING APPLICATIONS OF CRISPR/CAS9 at CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston   CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th  Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston http://www.discoveryontarget.com/ http://www.discoveryontarget.com/crispr-therapies/ #BostonDOT16 @BostonDOT […]

Read Full Post »


LIVE 9/19 8AM – 10AM USING CRISPR/Cas9 FOR FUNCTIONAL SCREENING CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston http://www.discoveryontarget.com/ http://www.discoveryontarget.com/crispr-therapies/ Meeting #: #BostonDOT16 Meeting @: @BostonDOT Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a Media Partner of CHI for CHI’s 14th Annual Discovery on Target taking […]

Read Full Post »


Licensing Agreements for CRISPR/Cas9 Genome Editing Technology Patent Curator: Aviva Lev-Ari, PhD, RN AstraZeneca’s CRISPR research collaborations are with the following institutions: The Wellcome Trust Sanger Institute, Cambridge, UK Under the terms of the collaboration with the Wellcome Trust Sanger Institute, research will focus on deleting specific genes relevant to cancer, cardiovascular, metabolic, respiratory, autoimmune […]

Read Full Post »

Next »